Table 3 Results of compliance to updated guidelines
| Â | Compliance, n (%) | P (a) | P (b) | P (c) | P (d) | P (e) | P (f) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Baseline group PERIOD 0 | Test Group PERIOD 1 | Post-test group PERIOD 2 | Post-computerized tool group PERIOD 3 | First group of the COVID-19 period PERIOD 4 | Second group of the COVID-19 period PERIOD 5 | Comparing the baseline group with the test group | Comparing the test group with the post-test group | Comparing the post-test group with the post-computerized tool group | Comparing the post-computerized tool group with the first group of the COVID-19 period | Comparing the first group of the COVID-19 period with the second group of the COVID-19 period | Comparing the second group of the COVID-19 period with the post-computerized tool group |
Indication | 125 (96.2) | 118 (100) | 121 (97.6) | 118 (98.3) | 108 (93.1) | 148 (97.4) | 0.03* | 0.09 | 0.68 | 0.046* | 0.09 | 0.09 |
Drug agent(s) | 108 (83.1) | 115 (97.5) | 111 (89.5) | 111 (92.5) | 101 (87.1) | 133 (87.5) |  < 0.01* | 0.01* | 0.42 | 0.17 | 0.92 | 0.92 |
Dose(s) | 106 (81.5) | 115 (97.5) | 111 (89.5) | 105 (87.5) | 98 (84.5) | 126 (82.9) |  < 0.01* | 0.01* | 0.62 | 0.50 | 0.73 | 0.73 |
Route of administration | 113 (86.9) | 117 (99.2) | 118 (95.2) | 115 (95.8) | 106 (91.4) | 137 (90.1) |  < 0.01* | 0.06 | 0.80 | 0.16 | 0.73 | 0.73 |
Time of pre-operative dose administration | 98 (77.2) | 99 (91.7) | 97 (78.9) | 88 (75.2) | 86 (76.8) | 117 (79.6) |  < 0.01* |  < 0.01* | 0.50 | 0.78 | 0.59 | 0.59 |
Number of administration(s) | 56 (43.1) | 88 (74.6) | 67 (54.0) | 68 (56.7) | 51 (44.0) | 85 (55.9) |  < 0.01* |  < 0.01* | 0.68 | 0.05 | 0.05 | 0.05 |
Duration of prophylaxis | 107 (83.6) | 114 (96.6) | 105 (84.7) | 108 (90) | 101 (87.1) | 136 (90.7) |  < 0.01* |  < 0.01* | 0.21 | 0.48 | 0.35 | 0.35 |